Avtor/Urednik | Šmid, Lojze; Zakotnik, Branko; Lešničar, Hotomir; Budihna, Marjan; Šoba, Erika; Furlan, Ladica; Žargi, Miha; Fajdiga, Igor; Župevc, Avgust | |
Naslov | Kombinirano zdravljenje neoperabilnih karcinomov v področju glave in vratu | |
Prevedeni naslov | Combined treatment for inoperable head and neck cancer | |
Tip | članek | |
Vir | Med Razgl | |
Vol. in št. | Letnik 35, št. Suppl 6 | |
Leto izdaje | 1996 | |
Obseg | str. 151-8 | |
Jezik | slo | |
Abstrakt | A prospectively designed randomized clinical study was undertaken to assess the efficacy of simultaneous application of irradiation, mitomycin C and bleomycin in treatment of patients with inoperable head and neck carcinoma. In oropharyngeal cancer patients, the difference in complete response rate between those who were only irradiated (31 %) and patients treated with simultaneous application of irradiation and chemotherapy (59 %) was statistically significant (p = 0,007). The difference in disease-free survival as well as in overall survival between both groups of these patients was statistically significant (p = 0,001), (p = 0,019). For all other subgroups added together, there was no benefit observed from the tested combined treatment. | |
Izvleček | V pregledni naključni klinični študiji avtorji ocenjujejo učinkovitost zdravljenje bolnikov z neoprabilnim karcinomom v področju glave in vratu s kombinacijo obsevanja, mitomicina C in bleomicina. Razlika v odstotku popolnih odgovorov karcinoma ustnega žrela na zdravljenje je bila med skupino bolnikov, ki so bili samo obsevani (31 %) ter skupino, v kateri so bolniki poleg obsevanja sočasno prejemali tudi citostatika (59 %), statistično značilna (p = 0,007). Tudi razlika v preživetju brez bolezni ter celokupnem preživetju je bila med obema skupinama teh bolnikov statistično značlnla (p = 001 oz. p = 0,019). Pri bolnikih s karcinomom drugih mest v področju glave in vratu razlike v številu popolnih odgovorov ter v preživetju med obema načinoma zdravljenja ni bilo. | |
Deskriptorji | HEAD AND NECK NEOPLASMS COMBINED MODALITY THERAPY SURVIVAL RATE |